Scientists hunt for clues to predict who benefits from head and neck cancer drug
NCT ID NCT04603248
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 50 people with advanced head and neck cancer that had stopped responding to chemotherapy. Researchers gave them the drug nivolumab and analyzed their tumors and blood to find biological markers that could predict who would respond best. The goal was to improve patient selection for this treatment, since not everyone benefits from it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab
What this could lead to
If successful, this could help doctors identify which head and neck cancer patients are most likely to benefit from nivolumab, making treatment more personalized and effective.
What could go wrong
This was a small, exploratory study (50 people) focused on finding biomarkers, not proving a new treatment works. The results may not lead to immediate changes in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea